Dr. Hans Keirstead is an internationally recognized stem cell expert and entrepreneur in regenerative medicine. He has pioneered therapies for cancer, immune disorders, motor neuron diseases, spinal cord injury, retinal diseases, immune disorders, and age-related immune decline, and created a novel multi-pathogen vaccine kit. Each of Dr. Keirstead’s three prior biotechnology firms was sold to major pharmaceutical companies for 2.5X-9.5X returns to investors, after return of investment capital. Currently, he holds board Chair positions in several leading biotechs including AIVITA Biomedical, Immunis Inc., and the global non-profit,Human Immune Project. During his 15-year tenure at the University of California Irvine, Dr. Keirstead mentored over 100 students, published over 150 manuscripts, and granted over 20 patents. His international media recognition includes being listed as one of Discover Magazine’s top 100 scientists, and highlights in Newsweek, WIRED, The New York Times, TIME Magazine, Science, TEDx and more. His scientific accomplishments have also been covered on 60 Minutes, PBS, and ABC news radio. Some of Dr. Keirstead’s notable awards include the “Top 20 Canadians” Award by the Consul General of Canada, “Best Entrepreneur,” by Corporate LiveWire, “Best Immune Treatment” by Global Health and Pharma, OCBJ’s “Innovator of the Year,” NIH Solowey award for the outstanding national researcher of the year, recognition as a world thought leader at the Seven Wonderer's event by Beakerhead, and the Cameron Award for the best PhD in the country. Dr. Keirstead received his Ph.D. in neuroscience from the University of British Columbia, Canada and pursued his postdoctoral research at the University of Cambridge, England.